[A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine].

Abstract

A controlled clinical trial, corresponding to stage 2, was conducted in a population of sound adult males aged 18-23 to evaluate the immunogenicity of 5 schedules of Cuban vaccine against hepatitis B (Heberbiovac-HB [correction of Cheberbiovac-HB]). 5 groups were studied: I (control group 0, 1 and 6 months), II (0 and 2 months), III (0 and 4 months), IV (0 and 6 months), and V (0 and 8 months). The results showed no significant differences as regards the percentage of seroprotection of any of the groups of 2 doses compared with the control of 3 doses. It is concluded that between the first and the second dose there may be a period of time from 2 to 6 months with no need to reinitiate the schedule. This information will serve as a basis for a population based study to determine which schedule is the best to be used.

• Authors: M de J González-Griego, Z Cinza, A Ortega, M M Gali, M E Santoyo, G García, A Delahanty
• Journal: Revista cubana de medicina tropical (Rev Cubana Med Trop) Vol. 50 Issue 3 Pg. 218-20 ( 1998) ISSN: 0375-0760 [Print] Cuba
• Vernacular Title: Estudio comparativo entre diferentes esquemas de administración de 2 dosis con la vacuna cubana antihepatitis B.
• PMID: 10349448 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Hepatitis B Antibodies
• Hepatitis B Vaccines
• Vaccines, DNA
• heberbiovac-HB

Topics

• Adolescent
• Adult
• Cuba
• Dose-Response Relationship, Immunologic
• Hepatitis B Antibodies (blood)
• Hepatitis B Vaccines (administration & dosage, immunology)
• Humans
• Immunization Schedule
• Male
• Time Factors
• Vaccines, DNA (administration & dosage, immunology)